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ChimeriVaxA live chimeric vaccine virus against Japanese encephalitis (JE), ChimeriVax-JE, was used to deﬁne methods
for optimal, random insertion of foreign immunologic determinants into ﬂavivirus glycoproteins. The
conserved M2e peptide of inﬂuenza A virus was randomly inserted into the yellow fever-speciﬁc NS1
glycoprotein of ChimeriVax-JE. A technique combining plaque puriﬁcation with immunostaining yielded a
recombinant virus that stably expressed M2e at NS1-236 site. The site was found permissive for other inserts.
The insertion inhibited NS1 dimerization in vitro, which had no signiﬁcant effect on virus replication in vitro
and immunogenicity in vivo. Two different NS1-speciﬁc monoclonal antibodies and a polyclonal antibody
efﬁciently recognized only the NS1 protein dimer, but not monomer. Adaptation of the virus to Vero cells
resulted in two amino acid changes upstream from the insert which restored NS1 dimerization. Immunized
mice developed high-titer M2e-speciﬁc antibodies predominantly of the IgG2A isotype indicative of a Th1-
biased response.
© 2009 Elsevier Inc. All rights reserved.Introduction
The use of viruses as delivery vehicles of foreign antigens offers the
opportunity to develop a variety of new recombinant live attenuated
vaccines. The Flavivirus genus of the Flaviviridae family includes
several major arthropod-borne human pathogens, such as yellow
fever (YF), dengue types 1–4, Japanese encephalitis (JE), West Nile
(WN), and tick-borne encephalitis (TBE) viruses (Gubler et al., 2007).
Flaviviruses are small enveloped plus-strand RNA viruses. The viral
particle contains a nucleocapsid composed of viral RNA and capsid
protein C which is surrounded by a lipid bi-layer with the envelope
glycoprotein E and membrane protein M. The E protein is the main
ﬂavivirus immunogen eliciting virus-neutralizing antibodies. The
genomic RNA is about 11,000 nt in length. It contains a single long
open reading frame (ORF). Translation of the ORF produces a single
polyprotein precursor containing viral proteins in the order: C-prM-E-
NS1-NS2A-NS2B-NS3-NS4A-2K-NS4B-NS5, where the structural C-
prM-E proteins (prM is a glycoprotein precursor for mature
unglycosylated M) are followed by nonstructural (NS) proteins NS1-
NS5, the components of the viral replication complex. The polyprotein
is processed by cellular and viral NS2B/NS3 proteases to yield
individual proteins (Lindenbach et al., 2007). The NS1 protein is.com (K.V. Pugachev).
ll rights reserved.essential for ﬂavivirus RNA synthesis (Muylaert et al., 1997;
Lindenbach and Rice, 1999). It is also the only NS protein that is
glycosylated and delivered to the cell surface, as well as secreted from
infected cells. The secreted NS1 forms dimers and possibly higher
order oligomers that can be dissociated by heat (Winkler et al., 1988;
Crooks et al., 1994; Hall et al., 1999; Flamand et al., 1999). A strong
humoral immune response is induced against this protein, and the
antibodies cause complement-mediated lysis of infected cells, which
contributes to protection from disease (Brandt et al., 1970; Schle-
singer et al., 1985, 1987; Lindenbach and Rice, 2003; Timofeev et al.,
2004; Burke and Monath, 2001). Recent studies have indicated that
NS1 protein of West Nile virus is involved in immune evasion through
interference with the complement system (Chung et al., 2006) and
inhibition of TLR3 mediated signal transduction (Wilson et al., 2008).
We have developed a new ChimeriVax technology for creation of
live vaccines against ﬂavivirus diseases, speciﬁcally JE, dengue and
WN, which are either being tested in Phase II/III clinical trials, or
submitted for licensure in the case of ChimeriVax-JE (IMOJEV™). This
technology takes advantage of the live attenuated YF 17D vaccine virus
in which the prM-E envelope protein genes are replaced with those
from corresponding heterologous ﬂaviviruses, resulting in highly
attenuated and immunogenic chimeric viruses of the heterologous
antigenic speciﬁcity (selected ref. Chambers et al., 1999; Guirakhoo et
al., 1999, 2001, 2002, 2006; Monath et al., 2003, 2006; Pugachev et al.,
2003). The YF 17D vaccine developed in the 1930s has been regarded
as one of the most successful human vaccines, with more than 400
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presenting cells (Querec et al, 2006; Barba-Spaeth et al., 2005; Palmer
et al., 2007), and induces robust and durable, possibly life-long
immunity after a single dose (Monath et al., 2008). The possibility of
foreign antigen delivery by YF17D and other ﬂaviviruses and
ﬂavivirus-based replicon vectors has been pursued by several groups
(McAllister et al., 2000; Barba-Spaeth et al., 2005; Tao et al., 2005;
Jones et al., 2005; Bredenbeek et al., 2006; Gehrke et al., 2005; Pijlman
et al., 2006). While immunogenicity of ChimeriVax vaccines is similar
to YF 17D, they are signiﬁcantly more attenuated in animal models
(Pugachev et al., 2003). We have initiated studies aimed at developing
ChimeriVax vaccines as expression/vaccine vectors to generate
vaccine candidates against non-ﬂavivirus pathogens.
In this study, we set out to establish methods for efﬁcient insertion
of immunodominant foreign epitopes into glycoproteins of Chime-
riVax vaccine viruses, speciﬁcally the YF 17D-speciﬁc NS1 protein of
ChimeriVax-JE, and isolation of insert-containing mutant clones. The
23-amino acid N-terminal ectodomain of theM2protein of inﬂuenza A
virus (M2e peptide) was used as a model antigen for direct (see
below) transposon-mediated insertion mutagenesis. It represents a
linear B-cell epitope that is highly conserved in all human inﬂuenza A
viruses and provides protection from infection in animalmodels, likely
through NK cell-mediated antibody-dependent cellular cytotoxicity
(ADCC) (Jegerlehner et al., 2004). Universal/pandemic inﬂuenza A
vaccine candidates based on M2e are currently in preclinical and
clinical stages of development (Neirynck et al., 1999; De Filette et al.,
2008; Huleatt et al., 2008; Fu et al., 2009; Schotsaert et al., 2009).
To ensure that the introduced M2e is at an optimal location within
NS1, not interfering with efﬁcient virus replication, a library of mutant
viral genomes was generated, containing the epitope inserted
randomly within the NS1 protein gene. Following transfection of
cells with the library, viable insert-containing variants were quickly
isolated by a technique combining plaque puriﬁcation and immunos-Fig. 1. Construction of a ChimeriVax-JE cDNA library with random insertions of inﬂuenza viru
and methods). The NS1 gene was subcloned and subjected to Tn7 insertion mutagenesis. Tn
The NS1-M2e gene library was ligated into a ChimeriVax-JE single-plasmid infectious clone.
Vero cells were transfected with the RNA transcripts, followed by isolation of individu
immunostaining. The sequence of the inserted M2e epitope with two C residues changed t
residues on both sides, and three additional residues (FEP) at the C-terminus encoded by ttaining of cells with an M2e monoclonal antibody. As a result of this
process, we generated and characterized both in vitro and in vivo a
ChimeriVax-JE/NS1-M2e recombinant containing the M2e epitope
inserted at residue 236 of the NS1 protein.
Results
Random insertion of M2e into the NS1 protein of ChimeriVax-JE virus
The ChimeriVax-JE infectious cDNA is propagated in two plasmids
that are ligated prior to in vitro transcription and recovery of virus
(Chambers et al., 1999). In this system, the yield of in vitro RNA
transcripts is relatively low. To increase the yields of in vitro
transcription (to be able to produce representative mutant RNA
libraries), we ﬁrst assembled a single-plasmid construct, pBSA,
containing the entire cDNA of ChimeriVax-JE virus under the control
of the SP6 promoter in a low-copy number vector pBeloBac11.
Additional restriction sites SphI, NsiI, and EagI, necessary for
subcloning of the prM, E, and NS1 genes, were then introduced into
pBSA by silent site-directed mutagenesis resulting in plasmid pBSA-
AR3 (Fig. 1).
A modiﬁed inﬂuenza A M2e epitope containing two C to S amino
acid changes to avoid any unwanted disulﬁde bridging (SLLTEVET-
PIRNEWGSRSNDSSD; the changed residues are underlined) was used
as a model peptide for insertion. The changes do not affect the
antigenicity/immunogenicity of the peptide (A. Birkett, personal
communication). The epitope with ﬂanking GG residue linkers (and
additional C-terminal FEP residues resulting from incorporation of a
BstBI cloning site to facilitate constructions) was randomly inserted
into the NS1 gene of ChimeriVax-JE cDNA (Fig. 1). We employed a
direct insertion method, in which transposon Tn7 is used to randomly
incorporate a unique insertion site PmeI throughout NS1 gene,
followed by insertion of M2e-encoding DNA fragment resulting in as epitope M2e in the NS1 protein. Major construction steps are illustrated (seeMaterials
7 transprimers were replaced with the M2e insert via randomly introduced PmeI sites.
To produce virus, the ﬁnal pBSA-AR3-rM2e plasmid library was transcribed in vitro, and
al M2e-positive viral clones using a technique combining plaque puriﬁcation and
o S (shown in gray) is provided at the bottom. The M2e sequence is ﬂanked by two G
he BstBI site necessary for kanamycin selection are shown (in gray).
Fig. 2. Expression of M2e and other epitopes within the NS1 protein of ChimeriVax-JE virus demonstrated by immunostaining of viral plaques. (A) Immunostaining with M2e MAb
(left images) or JE polyclonal antibody (right images) of Vero cells infected with viruses recovered immediately after RNA transfection (up to 0.4% of M2e-positive plaques in the
virus population; top panels), and after several rounds of plaque puriﬁcation (100% of M2e positive plaques; bottom panel). Cells in 24-well plates were infected, overlaid with
methylcellulose, and stained on day 4–5 post-infection. (B) Expression at the NS1-236 site of a 56-a.a. insert composed of the human inﬂuenza A M2e peptide followed by a partial
avian H5N1 inﬂuenza A M2e peptide. Infected Vero cells in a 24-well plate were immunostained with either the M2e Mab or JE HIAF. (C) Expression of HA-tag epitope at NS1-236.
HA-tag positive plaques were detected by immunostaining with a 12CA5 MAb.
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human-codon optimized, and modiﬁed to reduce the number of
alternative translational frames (three of possible ﬁve alternative
frames were ablated by introduction of stop codons) to increase theFig. 3. TheA25 clone of ChimeriVax-JE/NS1-M2evirus. (A) Location of the insert atNS1-236. Th
are in italic; the BstBI restriction site (TTCGAA) is underlined. Fifteen additional nucleotides we
preceding the insert (SV) were duplicated at the end of the insert (asterisks). Nucleotide and
from virus adaptation in Vero cells are shown (bold). (B) Plaquemorphologies of the A25 virus
days post-infectionwithM2e and JE-speciﬁc antibodies, respectively. (C) Growth curves of the A
PFU/cell. Viral titerswere not signiﬁcantly different at any time point, except for day 1 between
not statistically different by two-way ANOVA (pN0.05). Mean values from three experimentsproportion of virus mutants recovered after transfection containing
the insert in the desired frame/orientation. During all steps of Tn7-
mediated insertionmutagenesis, the determined numbers of clones in
plasmid libraries were many-fold higher than the number of nucleo-eM2e aminoacid sequence is boxed.Non-viral nucleotide sequences at the insert junctions
re added due to the action of the transposon (double underlined); two viral a.a. residues
amino acid substitutions at the N-terminal junction of the A25 P12 virus which resulted
at P2 and P12 passages as compared to parental ChimeriVax-JE. Vero cells were stained 4
25 virus at P2 and P12 as compared to ChimeriVax-JE vector virus in Vero cells; MOI 0.001
A25P2 and ChimeriVax-JE viruses (asterisk; pb0.05, t-test). Growth curveswere also found
were plotted, error bars represent standard deviations.
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insert was incorporated after every nucleotide (see Materials and
methods). Propagation of only Tn7/insert-containing plasmid var-
iants was facilitated by applying antibiotic selection. The representa-
tiveness of libraries was ascertained by PCR and restriction digestions.
The ﬁnal pBSA-AR3-rM2e plasmid library, containing random M2e
insertions in the NS1 gene of ChimeriVax-JE cDNA, was transcribed in
vitro, and Vero cells were transfected with the RNA transcripts. Viral
titers in harvested samples were determined by immunofocus assay
using staining of cell monolayers with JE hyper-immune ascitic ﬂuid
(HIAF) to quantitate total virus, or amonoclonal antibody (MAb) 14C2
against inﬂuenza A M2e epitope to quantitate virus expressing M2e.
Overall titers were in excess of 7 log10 PFU/ml. M2e-positive plaques
were readily detectable and represented up to 0.4% of total plaques
(e.g., Fig. 2A, upper panels). Some of these M2e-positive plaques were
as large as M2e-negative plaques, indicating efﬁcient replication of
insertion mutants. The fact that the majority of total plaques were
M2e negative may have several possible explanations, such as (i)
instability of the insert at some locations in NS1, resulting in
appearance of insert-less virus variants shortly after transfection,
(ii) the insert at some locations was inaccessible to the antibody, and
(iii) DNA encoding the insert was introduced in one of the two
remaining alternative reading frames.
In order to quickly purify individual M2e-positive clones, we
adapted a technique recently described for cloning of non-cytolytic
hantaviruses (Rang et al., 2006). In one variation of the approach, cells
infected with the virus-containing supernatant harvested after
transfection were overlaid with agarose. On day 5, the agarose was
removed and placed aside, and the underlying monolayer was stained
with M2e Mab. Portions of agarose corresponding to M2e-positive
plaques/foci were then harvested. Clones were puriﬁed to homoge-
neity by two to three additional rounds of plaque puriﬁcation/
immunostaining and then ampliﬁed by two passages in Vero cells to
result in P2 research stocks (passage 2 after last puriﬁcation step) (Fig.
2A, bottom panel). Stocks of 13 clones were produced by this
approach. The advantage of this approach is that after transfection, the
virus library is allowed to replicate in Vero cells (for up to 6 days), and
presumably only highly replication-competent M2e-positive clones
that are able to compete with M2e-negative virus are isolated from
the cell supernatant. In a second variation of the approach, transfected
cells were immediately overlaid with agarose, eliminating competi-
tion between variants, and M2e-positive clones were puriﬁed. This
was expected to allow for isolation of both efﬁciently replicating
clones as well as clones that grew less well. Several additional clones
were prepared using this approach.
Characterization of M2e-containing clones in vitro
Titers of the 13 P2 stocks derived from the post-transfection
supernatant were determined to be in the range of 2.6×106–1.0×107
PFU/ml. Plaque sizes of the clones were approximately half the size
of the ChimeriVax-JE parent (e.g., Fig. 3B). Importantly, staining with
both the M2e MAb and JE HIAF produced nearly identical titers,
demonstrating that the viral stocks were pure; this result also was
the ﬁrst evidence of high stability of the insert. In addition, efﬁcient
M2e staining of viral plaques was observed both with methanol
permeabilization of cells (detecting intracellular and surface protein)
and without (detecting only surface protein) (data not shown). Thus,
NS1 protein containing M2e peptide was transported to the surface
of infected cells, which is necessary for the induction of anti-M2e
antibody response in vivo.
The NS1 gene of the 13 clones was sequenced to determine the
locations of the M2e insert. The 35-a.a. insert (including ﬁve residues
that are remnants of Tn7) was found to be located at the same site in
all clones, in the middle of the protein between a.a. residues 236 and
237. The sequence of the insert and surrounding amino acids is shownin Fig. 3A. One of the clones, referred to as A25, was selected for
further characterization. A possible explanation for the insert being
present in the same location in all of the clones is the competition
between variants that occurred during virus replication after
transfection, resulting in enrichment of one highly replication
competent variant. However, several additional clones puriﬁed
immediately after transfection had the same M2e insertion location
as A25 virus, at NS1-236 (data not shown). It should be noted that in
the latter case, most of the candidate clones picked at the ﬁrst round of
puriﬁcation were lost on subsequent rounds, likely because they grew
relatively poorly which precluded efﬁcient recovery from agarose.
These observations suggest that there may be very few highly
permissive sites in the NS1 protein, or only one at a.a. NS1-236,
allowing isolation by the described (likely very stringent) method.
To determine whether the selected A25 clone is genetically stable,
it was passaged 10 times, to P12, at an estimated MOI of 0.001 PFU/
cell in Vero cells. Titration of the P12 sample by immunofocus assay
revealed that staining with both M2e MAb and JE HIAF yielded the
same titer of 8 log10 PFU/ml, and thus all viral particles contained the
insert. This demonstrated a very high stability of the insert. During
passages, the virus becamemore cytopathic, and the average diameter
of P12 virus plaques became larger than P2 virus and similar to
ChimeriVax-JE (Fig. 3B).
Growth kinetics of the A25 clone at P2 and P12 levels were
compared to ChimeriVax-JE vector in Vero cells. The result of three
representative experiments (MOI 0.001) is shown in Fig. 3C. P2 virus
grew efﬁciently, but somewhat slower than the ChimeriVax-JE parent.
P12 virus grew faster and peaked at a titer that was higher than
ChimeriVax-JE, in excess of 7 log10 PFU/ml on day 5. Thus, Vero cell
adaptation of A25 virus resulted in more efﬁcient replication,
although the curves did not differ statistically.
To establish the nature of adaptation during passages in Vero cells,
the full genome of the P12 virus was sequenced. Nine nucleotide
changes were detected, all within the ORF outside known cis-acting
elements necessary for efﬁcient RNA replication. Four of the changes
resulted in amino acid substitutions, V to A in the E protein at residue
E-357, M to V at NS4B-95, and two substitutions immediately
upstream from the M2e peptide, S to L at residue NS1-235, and F to
L at the ﬁrst insert residue located after NS1-236 which is not part of
M2e (see in Fig. 3A). None of these changes are reversions of
attenuating mutations in the ChimeriVax-JE vaccine (Guirakhoo et al.,
1999). The insert at NS1-236 was engineered into ChimeriVax-JE viral
cDNA, with and without the two upstream amino acid adaptations,
and viruses were recovered following transfection of cells with in
vitro RNA transcripts. Similarly to the growth curves in Fig. 3C, virus
that contained the two changes in NS1 grew to a peak titer higher than
virus without adaptations (data not shown). Thus the two amino acid
changes in the NS1-M2e hybrid protein were responsible for the
higher rate of P12 virus replication in vitro compared to P2 virus,
possibly due to a conformational change improving function of the
NS1-M2e protein.
Next, permissiveness of the NS1-236 site to longer inserts was
examined by inserting an additional (partial) consensus M2e epitope
of avian inﬂuenza A viruses (SLLTEVETPTRNEWESR; 17 a.a. long)
taking advantage of the BstBI site located downstream from the
human inﬂuenza A M2e epitope in the A25 virus (see in Fig. 3A). The
second insertion was ﬂanked at both ends by GG linkers added for
ﬂexibility, bringing the total size of insert to 56 a.a in length. A viable
virus was recovered following transfection of Vero cells as demon-
strated by immunofocus assay (Fig. 2B).
To determine whether the NS1-236 site was permissive for
epitopes other than M2e, an unrelated protective epitope from the
HA protein of H3 inﬂuenza A virus (HA-tag, SKAFSNSYPYDVPDYASL)
(Bui et al., 2007) ﬂanked by GG linkers at both termini was engineered
at the NS1-236 location, in place of M2e of A25 virus. Viable virus was
recovered following transfection as evidenced by immunostaining of
Fig. 4. Western blot analysis of NS1 (NS1-M2e) protein secreted from virus infected
cells. Media fromVero cells infectedwith A25P2, A25P12 or ChimeriVax-JE viruses (MOI
0.1 PFU/cell) was collected 60 h post-infection. Proteins in boiled (+) and unboiled (-)
samples of equal volume were separated by SDS-PAGE, and blots were stained with
antibodies: (A) YF-NS1 MAb 1A4, (B) polyclonal YF HIAF, and (C) M2e MAb. Titers of
infectious virus determined in the analyzed cell supernatants are shown at the bottom.
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recombinant viruses, encoding either the longer (2×M2e) or
heterologous (HA-tag) inserts at NS1-236, replicated efﬁciently in
Vero cells as evidenced by titers of 4.8×104 PFU/ml or higher upon
recovery. The inserts were stable as determined after three additional
passages in Vero cells (data not shown).
Effect of M2e insertion on NS1 protein secretion and dimerization
Media from Vero cells infected with the A25 P2 and P12 viruses, or
ChimeriVax-JE vector were analyzed by Western blot to determine
whether the M2e insertion at NS1-236 affected secretion or
dimerization of the NS1 protein. NS1 protein dimers are detected by
Western blot in unheated samples, and the nature of the dimerization
is unclear (Winkler et al., 1988). Samples were either boiled or
unboiled prior to SDS-polyacrylamide gel electrophoresis (to detect
monomeric and dimeric forms of the protein, respectively). StainingTable 1
M2e-speciﬁc antibody responses in mice.a
Group Route Antibody titers on
day 30 (GMT)
Antibody titers
(GMT and in po
Seroconverted Total IgG Total IgG
A25 P2 IP 8/8 1004 10,090
A25 P12 IP 6/8 155 3695
HBc-M2e/alum SC 8/8 4677 194,777
ChimeriVax-JE IP 0/8 b100 b100
a Mice were immunized and boosted 1 month later with 7 log10 PFU of indicated v
subcutaneously (SC). Titers of antibodies in sera of individual animals or in pooled sera w
geometric mean titer.
b Antibody titers determined in pools of sera are shown in parentheses.with MAb 1A5 against YF 17D NS1 protein of samples from
ChimeriVax-JE virus infected cells detected only the dimeric form of
NS1 (∼90 kDa; unboiled sample), but not monomeric NS1 (boiled
sample) (Fig. 4A). Thus, the MAb only reacts with the protein dimer.
Only a trace amount (or density) of dimeric NS1-M2e was detectable
by the MAb in the supernatant from A25 P2 virus-infected cells, while
a strong band of NS1-M2e dimer was observed for A25 P12 virus (Fig.
4A). As expected, NS1-M2e was of higher molecular weight as
compared to native NS1 of ChimeriVax-JE vector because of the
insertion. A similar result was obtainedwhen blots were stained using
another YF 17D NS1 MAb, 8G4 (data not shown); its binding epitope
does not overlap with that for MAb 1A5 (J. Schlesinger, personal
communication). Surprisingly, a polyclonal antibody against YF 17D
virus (YF 17D HIAF from ATCC) only reacted efﬁciently with the NS1
protein dimer in the supernatant from ChimeriVax-JE virus infected
cells, but not monomer. It detected a small amount/density of NS1-
M2e dimer in the A25 P2 sample, and a robust NS1-M2e band in A25
P12, respectively (Fig. 4B). Thus, staining patterns produced using
both the anti-NS1 MAbs and YF 17D virus polyclonal antibody were
similar. Because neither of these antibodies reacted well with the
monomers (which could be present in A25 P2 supernatant) it was
impossible to judge whether the M2e insertion in the A25 P2 virus
abrogated secretion or dimerization of its NS1-M2e protein. However,
the MAb 14C2 against linear M2e epitope detected both NS1-M2e
monomers and dimers in A25 P2 and A25 P12 samples (but not NS1 of
the ChimeriVax-JE parent) (Fig. 4C). The total amount of secreted
protein in the supernatants from cells infected with these viruses
appeared similar, proportional to the determined viral titers. This
observation was conﬁrmed in additional blots where volumes of
loaded samples were normalized by the infectious virus (data not
shown). In unboiled samples, most of the protein of A25 P2 virus
migrated as monomer, while most of the protein of A25 P12 was
clearly dimer (Fig. 4C). Therefore, we conclude that while the rate of
NS1 secretion is unaffected, the M2e insertion at NS1-236 location
impairs the ability of the protein to dimerize (in A25 P2 virus) that is
restored by the two adaptive mutations upstream from the insert in
A25 P12 virus.
Immunogenicity of ChimeriVax-JE/NS1-M2e A25 virus in mice
Four-week oldmicewere immunized with A25 P2 and P12 viruses,
or ChimeriVax-JE vector (7 log10 PFU/dose, IP), or HBc-M2e particles
representing a subunit vaccine control (10 μg formulated with 0.1 mg
of alum adjuvant, SC). The latter is composed of three copies of the
M2e peptide presented on the surface of hepatitis B core virus like
particle (Fiers et al., 2004; Neirynck et al., 1999). All mice were
boosted at 1 month after initial inoculation. M2e-speciﬁc antibody
titers were determined on day 30 (total IgG), before boost, and on day
59, after boost (total IgG, as well as IgG1, IgG2a, IgG2b and IgG3
isotypes) by ELISA in individual sera and/or in pools of sera (Table 1,
Fig. 5). Most A25 and HBc-M2e immunized animals seroconvertedafter boost on day 59
oled sera)b
IgG1 IgG2a IgG2b IgG3
2051 (8100) 5220 (24,300) 1298 (900) 900 (2700)
(300) (8100) (100) (300)
142,300 (218,700) 38,912 (72,900) 8100 (24,300) 2700 (2700)
b100 (b100) b100 (b100) b100 (b100) b100 (b100)
iruses intraperitoneally (IP) or with 10 μl of HBc-M2e adjuvanted with Alhydrogel
ere determined by end-point ELISA using synthetic M2e peptide as the antigen. GMT,
Fig. 5. M2e antibody responses in mice and post-challenge survival. M2e-speciﬁc total IgG ELISA titers in individual mice immunized with A25 P2 and P12 viruses, ChimeriVax-JE
control, and HBc-M2e particles/alum on day 30 (one dose) and day 59 (two doses) (panels A and B, respectively). Group geometric mean values are represented by horizontal lines.
Values in groups that were found to be not statistically signiﬁcant (t-test, pN0.05) are indicated by the same numbers, 1 and 2; other groups are statistically different. (C) ELISA titers
of M2e-speciﬁc IgG isotypes on day 59. GMT values of titers in individual animals or titers in pooled sera (asterisks) were plotted. Statistically signiﬁcant differences in values
between the A25 P2 and HBc-M2e immunized animals (t-test) are shown by brackets; others are not statistically different. (D) Percent survival of animals following inﬂuenza A
(H1N1) challenge on day 64 (IN route, mouse adapted A/PR/8/34 challenge virus, 16 LD50).
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group, had a borderline OD450 reading in the 1:100 serum dilution, the
limit of detection (Fig. 5A). After boost (day 59), all animals in the A25
P2 and P12, and HBc-M2e groups were seropositive, and total IgG
titers increased signiﬁcantly compared to day 30 (GMTs 10,090, 3695
and 194,777 for A25 P2, P12, and HBc-M2e, respectively; Table 1, Fig.
5B). While HBc-M2e/alum immunization resulted in a predominantly
Th2 type response, with IgG1 titers being highest among the antibody
isotypes, immunization with A25 P2 and P12 viruses resulted in a
predominantly Th1 type response as evidenced by higher IgG2a titers
(Table 1, Fig. 5C). IgG2a antibodies have been predominantly
implicated in M2e-mediated protection via the ADCC mechanism
(and to an extent, IgG2b and IgG3 antibodies) (Jegerlehner et al.,
2004). IgG2a titers elicited by the A25 viruses were in the same order
of magnitude as those elicited by HBc-M2e immunization, as judged
by titers in pooled sera of 24,300 and 72,900 in A25 P2 and HBc-M2e
groups, respectively (although GMTs in individual sera differed more
signiﬁcantly: 5220 and 38,912, respectively).
Antibody titers in sera of A25 P12 immunized animals were not
higher than in the A25 P2 groups, and thus the Vero cell adaptations
in the former virus (see above) did not improve virus replication in
mice. In addition, viruses with or without the NS1-M2e insert
replicated equally well in mice as was indirectly demonstrated in a
separate experiment where titers of JE-speciﬁc neutralizing anti-
bodies induced after a single IP dose were determined in pooled sera.
PRNT50 titers for A25 P2 and ChimeriVax-JE viruses were similar,
1280 and 2560, respectively.
Following challenge on day 64, one of ﬁve challenged mice in the
A25 P2 group survived (Fig. 5D). In the A25 P12 group, no animals
survived, however one of seven animals died on day 20, with a
signiﬁcant delay. All animals in the ChimeriVax-JE and mock-
immunized (negative control inoculated with diluent) groups died
by day 11. Five of seven animals (71%) immunized with HBc-M2e/alum survived, consistent with the higher M2e antibody titers in this
group. Thus, the A25 virus elicited a strong immune response against
M2e (e.g., a substantial IgG2a titer), which however was insufﬁcient
to provide a high level of protection from inﬂuenza A challenge in our
mouse model.
Discussion
The outstanding safety/immunogenicity characteristics of the
ChimeriVax live chimeric ﬂavivirus vaccines have prompted us to
initiate studies on the development of these viruses as vectors for
delivery of heterologous immunogens. Previously, we expressed
hepatitis C virus (HCV) structural proteins and immunodominant T-
and B-cell epitopes in complete ChimeriVax-JE virus. Short HCV
epitopes were inserted into the E protein rationally, based on the
knowledge of the E protein structure, or by indirect transposon-
mediated insertion. In the latter approach, the transposon was only
used to probe the target protein for permissive insertion locations,
followed by engineering of immunologic epitopes of interest in its
place by means of reverse genetics. This method is rather labor
intensive and can be unpredictable, as not every site permissive for a
transposon is equally permissive for other sequences that could lead to
inefﬁcient virus replication or insert instability; plus it does not ensure
optimal presentation to the immune system. HCV antigens were also
inserted intergenically (NS2B/NS3 junction) and in the 3′UTR. Results
from these studies indicated that short inserts (the C protein of HCV or
peptides) could be stably maintained in various insertion locations,
while longer inserts (e.g., HCV E1 and E2 envelope glycoproteins)
generally were not (Kleanthous et al., 2002), which was in agreement
with observations for TBE vectors (Gehrke et al., 2005).
In this study, we applied direct random Tn7-mediated mutagen-
esis to insert an immunologic determinant, the M2e peptide of
inﬂuenza A virus, into the NS1 glycoprotein of ChimeriVax-JE vaccine
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terms of vector virus replication and efﬁcient presentation to the
immune system. In contrast to rational insertion designs (Bonaldo et
al., 2002, 2006) or indirect random insertions, the intention in our
approach is to allow the virus to choose the most permissive insertion
location(s), which is achieved by isolation of efﬁciently replicating
insertion variants following transfection of cells with a representative
library of mutant viral genomes. This approach is particularly useful
when targeted protein structure is not known (e.g., ﬂavivirus NS1). By
analyzing a number of suchmutants in vivo, a variant can be identiﬁed
presenting a foreign epitope in the most immunogenic conﬁguration.
Even though transposon-mediated mutagenesis systems are
designed to produce libraries composed only of insert-containing
molecules, transfection of cells with libraries of mutant RNA trans-
cripts yielded only ∼0.4% of viral particles expressing M2e in our
experiments, and therefore the main challenge was isolation of pure
M2e-positive clones. In previous studies, where indirect transposon-
mediatedmutagenesiswas used to insert reporter sequences into viral
proteins, insert containing viral cloneswere generated from individual
plasmid clones (Brune et al., 1999; Moradpour et al., 2004; Das and
Pattnaik, 2005; Risatti et al., 2005; Navaratnarajah and Kuhn, 2007).
Alternatively, in the case of direct insertion of ﬂuorescent proteins,
such as GFP, identiﬁcation and isolation of insert-containing virus
mutants following transfection with RNA libraries was facilitated by
taking advantage of ﬂuorescence of infected cells (Atasheva et al.,
2007; Frolov et al., 2009). We adopted a puriﬁcation method
developed for noncytopathic viruses (Rang et al., 2006), and quickly
recovered ∼20 individual M2e-positive clones from agarose overlay
following their identiﬁcation by immunostaining of the underlying cell
monolayer. These insertion/puriﬁcation methods have been subse-
quently applied to the prM and E proteins of ChimeriVax-JE
(Rumyantsev et al., to be published elsewhere).
Surprisingly, all of the isolated ChimeriVax-JE/NS1-M2e clones
contained the M2e insert at the same location, after residue NS1-236.
Although our attempts to isolate additional mutants were not
exhaustive, this indicated that the NS1 protein is not highly
permissive in terms of alternative insertion locations. This was in
accordance with other recent observations that indicated limited
permissiveness of YF 17D virus NS1 as shown by linker scanning (R.
Kuhn, personal communication). One of the NS1-236-M2e clones,
A25, was characterized in detail in vitro and in vivo. It replicated
efﬁciently in Vero cells andmaintained theM2e insert duringmultiple
low-MOI passages (up to P12, the ﬁnal passage examined). Two
amino acid adaptations that occurred during passages in the NS1
protein immediately upstream from the insert slightly increased the
plaque size and virus titers. Additionally, we demonstrated that the
NS1-236 location appears to be broadly permissive as it tolerated well
both heterologous (HA-tag) and longer (56 a.a) inserts.
An importantﬁnding in this studywas thatwhile theM2e insertion
at NS1-236 location did not affect the rate of NS1 protein secretion
from A25 P2 virus-infected Vero cells, the ability of the hybrid protein
to dimerize was impaired. Interestingly, as few as two amino acid
adaptations, upstream from the insert in P12 virus, were sufﬁcient to
restore dimerization. Themolecularmechanism of dimerization of the
ﬂavivirus NS1 protein is unknown; however, it appears that the region
around residue 236 plays a critical role. Another striking ﬁnding in this
studywas that two distinctmonoclonal antibodies against YF 17DNS1
(1A5 and 8G4) were found to efﬁciently recognize the dimeric form of
the protein (in unboiled samples) in Western blots, but not NS1
monomer. Even more surprising, a polyclonal HIAF against YF 17D
virus, which was expected to have a broad repertoire of NS1
antibodies, also reacted strongly only with the dimer. These data
suggest that theremay be a single dominant, tertiary antigenic domain
in the NS1 protein, speciﬁcally in its dimer, which could be composed
of multiple conformational epitopes. Apparently the domain is
destabilized by the NS1-236-M2e insertion, and restored by twoupstream amino acid adaptations. The NS1 protein of ﬂaviviruses is an
attractive target for developing immunodiagnostic assays, including
by Western blot (Oceguera et al., 2007; Patiris et al., 2008). An NS1-
based assay could be particularly useful for distinguishing naturally
acquired immunity from immunity resulting from vaccination with a
corresponding ChimeriVax vaccine, e.g., wild type JE virus infection
from ChimeriVax-JE. Thus, attention should be paid to whether NS1
antibodies from subjects can react with the two forms of NS1, and
assays developed accordingly.
It has been shown for Kunjin and Murray Valley encephalitis
viruses that a single P to L amino acid change at a nearby residue NS1-
250 abolished NS1 protein dimerization, but not secretion, resulting in
reduced virus replication both in vitro (in contrast to our data for A25
described above) and in vivo based on peripheral virulence in mice,
and it was concluded that the dimeric form of NS1 is functionally
important (Hall et al., 1999; Clark et al., 2007). In our experiments,
neither the M2e insertion in A25 P2 virus nor the adaptations in the
P12 virus seemed to have any appreciable effect on ChimeriVax-JE
virus replication in vivo as demonstrated indirectly by measuring JE-
speciﬁc neutralizing antibody titers in immunized mice. Furthermore,
similar levels of anti-M2e antibodies were induced by A25 P2 and P12
viruses. It is possible that disruption of NS1 dimerization can have
different effects in the context of different ﬂaviviruses.
The NS1 protein of ﬂaviviruses is known to induce a strong
humoral response in animals, and therefore is considered an
appropriate delivery vehicle for foreign epitopes. We demonstrated
that the A25 virus was highly immunogenic in mice as it induced high
titers of M2e antibodies following immunization, albeit lower
compared to the subunit HBc-M2e control. As could be expected,
given the nature of the two immunogens, the virus elicited a primarily
Th1 type immune response as evidenced by signiﬁcantly higher IgG2a
M2e-speciﬁc antibody titers than IgG1 titers, while response to HBc-
M2e was Th2-biased, with IgG1 titers being higher than other
isotypes. This ﬁnding is important because for some target pathogens
a pronounced Th1 response is desirable, e.g., a balanced IgG2a/IgG1
antibody response to an RSV vaccine is believed to be necessary to
avoid disease exacerbation in vaccinated children exposed to RSV
infection (rev. Olson and Varga, 2008). Following inﬂuenza A virus
challenge, survival of mice immunized with A25 virus was lower
compared to HBc-M2e. IgG2a antibodies have been demonstrated to
be the most functionally important for cell lysis in ADCC (Jegerlehner
et al., 2004). Even though M2e-speciﬁc IgG2a titers were rather high
in A25-immunized animals, they were several-fold lower than in the
HBc-M2e group, which could be the reason for lower post-challenge
survival. However, we do not exclude the possibility that the high
levels of IgG1 antibodies induced by HBc-M2e played a role also,
perhaps through mechanisms other than ADCC. Passive protection of
mice and inhibition of inﬂuenza A virus replication in vitro have been
reported for the anti-M2 Mab 14C2 belonging to the IgG1 isotype
(Treanor et al., 1990).
Our data demonstrate that the described random insertion
approach could lead to new vaccines, particularly if neutralizing
epitopes are employed rather than non-neutralizing epitopes. Fur-
thermore, it is known that YF 17D and ChimeriVax vaccines replicate
more efﬁciently in non-human primates than in mice as judged by
post-inoculation viremia, and are signiﬁcantly more immunogenic
based on neutralizing antibody responses (reviewed in Pugachev et al.,
2003). Thus, further development of ChimeriVax virus vectors is
warranted.
Materials and methods
Cells and viruses
Vero cells obtained from the American Type Culture Collection
(ATCC, Manassas, VA) were propagated in MEM medium (Invitrogen,
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glutamine and an antibiotic–antimycotic mixture (Invitrogen). Cells
and viruses were grown at 37 °C, 5.0% CO2. The same medium, but
supplemented with 2% FBS, was generally used for propagation of
viruses.
Viral titers in cell culture suspensions were determined by
immuno-focus assay in Vero cells essentially as described previously
(Rumyantsev et al., 2006) by staining on 4–5 days post-infection with
anti-JE hyperimmune ascitic ﬂuid (JE HIAF; ATCC) or monoclonal
antibody (MAb) 14C2 against the ectodomain of inﬂuenza A M2
protein (Afﬁnity BioReagents, Thermo Fisher Scientiﬁc, Rockford, IL),
or anti-HA-tag MAb 12CA5 (Roche, Indianapolis, IN) as primary
antibodies, and the Envision anti-mouse IgG-horseradish peroxidase
(Dako, Carpinteria, CA) as the secondary antibody.
Plasmids and random insertion mutagenesis
The entire genome cDNA of ChimeriVax-JE virus was cloned into
the pBeloBac11 low-copy number vector (New England Biolabs,
Beverly, MA) to generate a single-plasmid construct, pBSA. The viral
genome in pBSAwas placed under the control of an SP6 promoter used
for in vitro RNA transcription. Additional restriction sites SphI, NsiI,
and EagI, necessary for subcloning of the prM, E, and NS1 genes, were
introduced into the pBSA plasmid by silent site-directed mutagenesis
(Single Site Mutagenesis kit; Stratagene, La Jolla, CA) resulting in
plasmid pBSA-AR3 (Fig. 1). The plasmid was stably propagated in
DH10B E. coli cells (Invitrogen) in the presence of chloramphenicol.
For insertionmutagenesis, the NS1 genewas subcloned into pUC18
(Fig. 1). The resulting pUC-AR03 plasmidwas randomlymutated using
a Tn7-based transposon linker scanning kit (GPS-LS System; New
England Biolabs) and used to transform E. coli (XL-1; Stratagene) that
were then grown in the presence of chloramphenicol. The resulting
plasmid library (pUC-AR03-Tn7) contained ∼17,000 transformants.
The mutated NS1 gene library from pUC-AR03-Tn7 was subcloned in
pUC18 vector resulting in pUC-AR03-Tn7enr library (∼106 transfor-
mants) in which only the NS1 gene sequence was mutated. The
transprimer was removed by PmeI digestion (pUC-AR03-rPmeI
library; 290,000 transformants), leaving behind only a 15-nt random
insert containing a unique PmeI site. To facilitate insertion of M2e, a
SmaI–SmaI cassette containing a fusion of M2e sequence and a
kanamycin resistance gene (Kanr) was ﬁrst assembled by PCR. The
cassette was inserted at the random PmeI sites in the pUC-AR03-rPmeI
library, which resulted in the library pUC-AR03-rM2e/Kan (20,000
transformants) grown in the presence of Kan. The Kanr gene was then
removed by digestion with BstBI resulting in library pUC-AR03-rM2e
(N105 transformants) containing only the random M2e gene inserts.
Prior to ligation of the NS1-M2e gene library into the full-length
infectious clone of ChimeriVax-JE, a lethal stop codon/frame shift
modiﬁcation was ﬁrst introduced into the NS1 gene of pBSA-AR3
plasmid, resulting in plasmid pBSA-AR3stop. The modiﬁcation
precludes any chances of recovery of virus from unmutated template.
The full-length template library for ChimeriVax-JE/NS1-M2e was
obtained by replacing the NS1 gene (KasI–EagI fragment) in pBSA-
AR3stop plasmid with NS1-M2e gene library from pUC-AR03-rM2e
(Fig. 1), resulting in pBSA-AR3-rM2e ﬁnal plasmid library (280,000
transformants) propagated in E. coli DH10B cells.
Puriﬁcation of M2e-containing clones
To produce virus with the consensus M2e epitope randomly
inserted in the NS1 protein, the pBSA-AR3-rM2e librarywas linearized
with XhoI and transcribed in vitro with SP6 RNA polymerase (Ampli-
Cap; Epicentre, Madison, WI), followed by transfection of Vero cells
with the RNA transcripts using Lipofectamine 2000 reagent (Invitro-
gen) or electroporation. Virus progeny was harvested when a
cytopathic effect was detectable (day 3–6 post-transfection). Verocells infected with serial dilutions of virus were overlaid with 0.6%
agarose in MEMmedium supplemented with 2% FBS. Alternatively, to
reduce the effect of competition between M2e-positive and M2e-
negative virus after transfection, Vero cells transfected with the in
vitro RNA transcripts were immediately overlaid with agarose.
Isolation of individual M2e-positive virus clones was then performed
using a technique combining plaque puriﬁcation with M2e MAb
staining (immuno-focus assay) of the underlying cell monolayer. On
day 5, agarosewas removed and stored in a Petri dish at 4 °C, while the
cell monolayer was immuno-stained with anti-M2 MAb 14C2. The
agarose was then aligned with the stained monolayer and portions of
the gel corresponding to positive M2e-plaques were harvested and
frozen. Candidate cloneswere puriﬁed to homogeneity by two to three
additional rounds using the same technique and ampliﬁed by two
passages in Vero cells to make P2 research stocks.
Western blot
To analyze the effect of M2e insert on expression and secretion of
the NS1 protein, Vero cells were infected with ChimeriVax-JE with or
without the M2e insert in NS1 at an MOI of 0.1 PFU/cell. Cell media
from infected cells were collected 60 h post-infection, clariﬁed by low
speed centrifugation, aliquotted and stored at -80 °C. Expressed
proteins were separated in 4–20% Tris-glycine gels (Invitrogen) using
boiled (to detect NS1monomers) or not boiled (to detect NS1 dimers)
reduced samples. After protein transfer from gels, blotting mem-
branes were immunostained using: (i) primary antibodies against
M2e (MAb 14C2; 1:10,000 dilution), MAbs against YF 17DNS1 protein
(1A5 and 8G4; 1:2000 dilution; provided by J. Schlesinger), or mouse
polyclonal ascitic ﬂuid against YF 17D virus (1:2000 dilution; ATCC);
(ii) secondary antibodies: goat anti-mouse IgG-alkaline phosphatase
(AP) conjugate (1:1000 dilution; Southern Biotech, AL).
Mouse experiments
All procedures were performed under approved protocols in
accordance with the National Institutes of Health (NIH) requirements
for humane treatment of laboratory animals. Balb/C mice were from
Taconic, Hudson, NY. Immunization, bleeding and challenge details
are described in Results. Challenge was done by the intranasal (IN)
route with 32 PFU (16 LD50) of mouse adapted inﬂuenza A/H1N1
virus (Puerto Rico 8/64). Moribund mice and animals that lost more
than 25% of body weight were humanely euthanized.
Antibody responses measured by ELISA and PRNT
Titers of anti-M2e antibodies were determined by standard ELISA
using synthetic M2e peptide at concentration 2 mg/ml to coat ELISA
plates. Sera from individual animals or pooled samples were serially
diluted in three-fold dilution steps, and added toM2e-coated plates in
duplicate wells. Secondary antibodies were goat anti-mouse total IgG,
IgG1, IgG2a, IgG2b and IgG3 AP conjugates (Southern Biotech). The
PNPP (para-nitro phenol phosphate) substrate was used as the
chromogen (Sigma, Saint Louis, MO). The absorbance was measured
at OD450 and the highest serum dilution with reading of ≥0.1 after
background subtraction was recorded as the end point titer.
A standard plaque reduction neutralization test (PRNT50) was
performed to measure JE-speciﬁc neutralizing antibody titers in
mouse sera against ChimeriVax-JE virus as previously described
(Guirakhoo et al., 1999).
Statistical analyses
Calculations of end point titers and analyses of statistical
signiﬁcance were performed using GraphPad Prism 5 (GraphPad
Prism Software, Inc., San Diego, CA).
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